Literature DB >> 24528021

Roles of PTEN (Phosphatase and Tensin Homolog) in gastric cancer development and progression.

Wen-Ting Xu1, Zhen Yang, Nong-Hua Lu.   

Abstract

Gastric cancer is highly invasive, aggressively malignant, and amongst the most prevalent of all forms of cancer. Despite improved management strategies, early stage diagnosis of gastric cancer and accurate prognostic assessment is still lacking. Several recent reports have indicated that the pathogenesis of gastric cancer involves complex molecular mechanisms and multiple genetic and epigenetic alterations in oncogenes and tumor suppressor genes. Functional inactivation of the tumor suppressor protein PTEN (Phosphatase and Tensin Homolog) has been detected in multiple cases of gastric cancer, and already shown to be closely linked to the development, progression and prognosis of the disease. Inactivation of PTEN can be attributed to gene mutation, loss of heterozygosity, promoter hypermethylation, microRNA- mediated regulation of gene expression, and post-translational phosphorylation. PTEN is also involved in mechanisms regulating tumor resistance to chemotherapy. This review provides a comprehensive analysis of PTEN and its roles in gastric cancer, and emphasizes its potential benefits in early diagnosis and gene therapy-based treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24528021     DOI: 10.7314/apjcp.2014.15.1.17

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  24 in total

1.  Integrated miRNA profiling and bioinformatics analyses reveal upregulated miRNAs in gastric cancer.

Authors:  Chen Yuan; Yue Zhang; Wenwen Tu; Yusheng Guo
Journal:  Oncol Lett       Date:  2019-06-19       Impact factor: 2.967

2.  Phosphorylated insulin-like growth factor-1 receptor expression predicts poor prognosis of Chinese patients with gastric cancer.

Authors:  Wen-ying Deng; Ning Li; Xiang-bin Wan; Su-xia Luo; You-wei Zhang
Journal:  Med Oncol       Date:  2014-10-28       Impact factor: 3.064

Review 3.  Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.

Authors:  Hui Jun Lim; Philip Crowe; Jia-Lin Yang
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-22       Impact factor: 4.553

4.  Inhibition of microRNA-181a may suppress proliferation and invasion and promote apoptosis of cervical cancer cells through the PTEN/Akt/FOXO1 pathway.

Authors:  Hongmei Xu; Jihong Zhu; Cong Hu; Hua Song; Yiyang Li
Journal:  J Physiol Biochem       Date:  2016-08-18       Impact factor: 4.158

Review 5.  The biochemical and clinical implications of phosphatase and tensin homolog deleted on chromosome ten in different cancers.

Authors:  Qinyi Wang; Junmin Wang; Hongjiao Xiang; Peilun Ding; Tao Wu; Guang Ji
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 6.  The Importance of Using Exosome-Loaded miRNA for the Treatment of Spinal Cord Injury.

Authors:  Yunpeng Shen; Junying Cai
Journal:  Mol Neurobiol       Date:  2022-10-24       Impact factor: 5.682

7.  Immunohistochemical classification of gastric cancer based on new molecular biomarkers: a potential predictor of survival.

Authors:  Cristina Díaz Del Arco; Lourdes Estrada Muñoz; Elena Molina Roldán; Mª Ángeles Cerón Nieto; Luis Ortega Medina; Soledad García Gómez de Las Heras; Mª Jesús Fernández Aceñero
Journal:  Virchows Arch       Date:  2018-08-23       Impact factor: 4.064

Review 8.  Posttranslational regulation of phosphatase and tensin homolog (PTEN) and its functional impact on cancer behaviors.

Authors:  Wenting Xu; Zhen Yang; Shu-Feng Zhou; Nonghua Lu
Journal:  Drug Des Devel Ther       Date:  2014-10-06       Impact factor: 4.162

Review 9.  Focus on PTEN Regulation.

Authors:  Miriam Bermúdez Brito; Evangelia Goulielmaki; Evangelia A Papakonstanti
Journal:  Front Oncol       Date:  2015-07-27       Impact factor: 6.244

10.  The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma.

Authors:  Tasuku Matsuoka; Masakazu Yashiro
Journal:  Cancers (Basel)       Date:  2014-07-07       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.